CureVac Goes After BioNTech Claiming Patent Infringement by Comirnaty’s mRNA Underpinnings

CureVac has filed a patent infringement lawsuit against BioNTech, claiming its messenger RNA (mRNA) technology was used without credit or compensation to create BioNTech’s and Pfizer’s Comirnaty, the world’s first approved COVID-19 vaccine and now the most widely used one.
Source: Drug Industry Daily